PMGC Holdings Inc. announced on January 15, 2025, the renaming of its wholly-owned subsidiaries as part of a strategic effort to better align with the company's evolving business focus as a diversified holding company.
Elevai Research Inc. has been renamed PMGC Research Inc., and Elevai Biosciences Inc. has been renamed Northstrive Biosciences Inc. These subsidiaries continue to focus on driving innovation in their respective fields.
PMGC Research Inc. is a research and development subsidiary leveraging Canadian research grants and university partnerships. Northstrive Biosciences Inc. is a biopharmaceutical company focusing on developing and acquiring aesthetic medicines, with its lead asset EL-22 targeting muscle preservation in obesity treatments.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.